Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$509.09 USD

509.09
180,132

+2.75 (0.54%)

Updated Nov 4, 2024 11:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Cerner's CommunityWorks Picked by Reeves County Hospital

Cerner (CERN) sees a slew of developments in its EHR platform, market prospects bright.

    Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

    Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.

      Abbott Banks on New Approvals and Buyouts, Competition Rife

      Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.

        Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global

        Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.

          Cerner Integrated Platform Implemented by Spectrum Health

          Spectrum Health selects Cerner's (CERN) Cerner Integrated Platform to treat psychological disorders.

            Insulet Advances on Omnipod Reimbursement Update, Runs Risks

            Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.

              Here's Why You Should Hold on to Align Technology (ALGN) Now

              Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.

                Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now

                AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.

                  Veeva's Vault CDMS to Unify Clinical Data in Single Platform

                  Veeva's (VEEV) cloud-based applications' market prospects bright.

                    Here's Why You Should Invest in Masimo (MASI) Right Now

                    A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.

                      ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

                      ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

                        QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

                        Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

                          Cooper's MiSight Lens Effective in Checking Juvenile Myopia

                          Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.

                            Can Intuitive Surgical (ISRG) Keep the Earnings Surprise Streak Alive?

                            Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                              Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                              Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                                CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise

                                A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.

                                  QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                                  QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.

                                    DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand

                                    DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.

                                      Omnicell Continues to Pursue Buyouts, Costs on the Rise

                                      Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

                                        Cardiovascular Systems Portfolio Strong, Competition Rife

                                        Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

                                          Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

                                          Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.

                                            Veeva Gains as MD&D Companies Pick Its Cloud-Based Services

                                            Veeva's (VEEV) focus on cloud-based services is likely to open up substantial opportunities for the company.

                                              Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%

                                              Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.

                                                Here's Why You Should Invest in Penumbra (PEN) Stock Now

                                                The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.

                                                  Sreyoshi Mukherjee headshot

                                                  3 Stocks to Watch as Bots Take Bigger Strides in US Healthcare

                                                  Robotics and mechatronics shape up the U.S. medical industry; three stocks that catch the eye.